Dr. Steve Nissen from Cleveland Clinic, a leading figure in lipoprotein(a) research, joins Dr. Greg Katz from NYU to delve into crucial insights about this underappreciated lipid layer. They discuss why Lp(a) is essential for evaluating cardiovascular risk and who should be tested. Listeners will learn about interpreting results, managing elevated levels, and the potential roles of aspirin and PCSK9 inhibitors. The episode highlights the evolving strategies in understanding and treating Lp(a), offering a fresh perspective on patient care.
Lipoprotein(a) is genetically determined and poses a significant independent risk for atherosclerotic cardiovascular disease, necessitating specific testing and management strategies.
Effective management of elevated LP(a) levels involves controlling other cardiovascular risk factors and counseling patients on lifestyle modifications and their overall health.
Deep dives
Understanding LP(a) and Its Unique Characteristics
LP little a (LP(a)) is a distinct subtype of low-density lipoprotein (LDL) that poses an independent risk for atherosclerotic cardiovascular disease (ASCVD). Unlike traditional LDL particles, LP(a) is genetically determined and characterized by the presence of a specific apolipoprotein A molecule on its surface, which contributes to heightened cardiovascular risks. Research has shown that individuals with elevated LP(a) levels face a significantly greater likelihood of coronary artery disease, with studies indicating a 2.3-fold increase in heart attack risk for those exceeding 50 mg/dL. The pathophysiological mechanisms of LP(a) include increased oxidation of phospholipids, pro-inflammatory properties, and the promotion of thrombosis, which collectively enhance its pro-atherogenic role.
Guidelines for Testing LP(a) Levels
The decision on when to test for LP(a) levels varies among medical guidelines, but it has been categorized into three main groups. Testing is recommended for secondary prevention in individuals with prior heart attacks or strokes that occur without traditional risk factors, those with recurrent ASCVD despite optimal management, and patients with a family history of premature cardiovascular disease. Primary prevention is also indicated for patients with borderline to intermediate risk profiles based on traditional risk assessments. Furthermore, some guidelines even advocate for testing all adults at least once, as approximately 20 to 25 percent of people have elevated LP(a), emphasizing the need for early identification.
Interpreting and Managing Elevated LP(a) Levels
Elevated LP(a) levels are assessed using different unit systems, with common thresholds indicating risk set at over 50 mg/dL or 125 nmol/L, indicating a correlation between higher levels and increased ASCVD risk. Effective management of patients with high LP(a) should prioritize controlling other cardiovascular risk factors, such as lowering LDL-C levels to below 55 mg/dL, maintaining optimal blood pressure, and addressing lifestyle factors, including smoking cessation and weight management. While therapies specifically targeting LP(a) are limited, clinicians often treat LDL levels aggressively, and emerging treatments like PCSK9 inhibitors show promise in reducing overall atherogenic particle numbers. However, the emphasis remains on comprehensive care in managing all cardiovascular risks associated with high LP(a).
Counseling Patients on LP(a) Results
When counseling patients about their elevated LP(a) levels, it's essential to provide context, reassuring them that while LP(a) is a risk factor, it is not the sole determinant of their cardiovascular health. Many patients may experience heightened anxiety regarding their risks, particularly if they perceive themselves as ticking time bombs; therefore, it's crucial to emphasize controllable risk factors. For those without a prior ASCVD event, informed management strategies should be implemented to minimize risks associated with other cardiovascular conditions. As future therapies become available for LP(a), proactive patient management and education surrounding lifestyle modifications and risk management remain critical components for long-term health outcomes.
What does Lipoprotein(a) tell us that a standard lipid panel doesn’t? Should we be testing everyone for it? Dive into the genetics, clinical implications, and evolving management strategies for Lp(a). Learn how to interpret results, counsel patients, and navigate topics with limited data like aspirin and PCSK9 inhibitors in treatment.
🔹 Sponsor: Freed is an AI scribe that listens and writes your note in < 30 seconds. Freed learns your style over time and is HIPAA compliant!
Use the code CORE50 to get 50% off your first month with Freed
(02:17) | Pearl 1: What makes Lp(a) unique? How does it raise ASCVD risk?
(10:32) | Pearl 2: Who should be tested for Lp(a)? When and why?
(16:54) | Pearl 3: Understanding and interpreting Lp(a) levels
(24:04) | Pearl 4: How does an elevated Lp(a) affect management?
(37:05)| Pearl 5: The role of aspirin and PCSK9 inhibitors in Lp(a)
Tags: CoreIM, Internal Medicine, Primary Care, Preventive Cardiology, Atherosclerosis, Lipid Management, Medical Education, IMCore, Physician Assistant, Nurse Practitioner, Medical Student
Find the best disability insurance for you: https://www.patternlife.com/disability-insurance?campid=497840
Our Sponsors: * Check out Thrive Market for 30% off your first order, plus a FREE $60 gift! : https://thrivemarket.com/coreim * Sponsor: FIGS! Use code FIGSRX for 15% off: https://wearfigs.com
